| [1] |
Zhao J, Lv WG, Feng FZ, et al. Placental site trophoblastic tumor: A review of 108 cases and their implications for prognosis and treatment[J]. Gynecol Oncol, 2016, 142(1):102-108. doi: 10.1016/j.ygyno.2016.05.006.
pmid: 27168005
|
| [2] |
Liu W, Zhao W, Huang X. Outcomes and prognostic factors of placental-site trophoblastic tumor: a retrospective study of 58 cases[J]. Arch Gynecol Obstet, 2022, 306(5):1633-1641. doi: 10.1007/s00404-022-06502-7.
pmid: 35279728
|
| [3] |
Gadducci A, Carinelli S, Guerrieri ME, et al. Placental site trophoblastic tumor and epithelioid trophoblastic tumor: Clinical and pathological features, prognostic variables and treatment strategy[J]. Gynecol Oncol, 2019, 153(3):684-693. doi: 10.1016/j.ygyno.2019.03.011.
pmid: 31047719
|
| [4] |
Baergen RN, Rutgers JL, Young RH, et al. Placental site trophoblastic tumor: A study of 55 cases and review of the literature emphasizing factors of prognostic significance[J]. Gynecol Oncol, 2006, 100(3):511-520. doi: 10.1016/j.ygyno.2005.08.058.
pmid: 16246400
|
| [5] |
Hassadia A, Gillespie A, Tidy J, et al. Placental site trophoblastic tumour: clinical features and management[J]. Gynecol Oncol, 2005, 99(3):603-607. doi: 10.1016/j.ygyno.2005.06.054.
pmid: 16085293
|
| [6] |
赵峻, 向阳. 妊娠滋养细胞肿瘤生育力保护研究现状[J]. 中国实用妇科与产科杂志, 2022, 38(11):1079-1083. doi: 10.19538/j.fk2022110105.
|
| [7] |
程红燕, 向阳. 妊娠滋养细胞肿瘤的免疫治疗[J]. 中国实用妇科与产科杂志, 2022, 38(7):693-696. doi: 10.19538/j.fk2022070107.
|
| [8] |
Schmid P, Nagai Y, Agarwal R, et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study[J]. Lancet, 2009, 374(9683):48-55. doi: 10.1016/S0140-6736(09)60618-8.
pmid: 19552948
|
| [9] |
Hamanishi J, Mandai M, Ikeda T, et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer[J]. J Clin Oncol, 2015, 33(34):4015-4022. doi: 10.1200/JCO.2015.62.3397.
pmid: 26351349
|
| [10] |
Bolze PA, Patrier S, Massardier J, et al. PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes[J]. Int J Gynecol Cancer, 2017, 27(3):554-561. doi: 10.1097/IGC.0000000000000892.
|
| [11] |
Ghorani E, Kaur B, Fisher RA, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia[J]. Lancet, 2017, 390(10110):2343-2345. doi: 10.1016/S0140-6736(17)32894-5.
pmid: 29185430
|